Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients

Ochiai, Hiroki; Ohishi, Takashi; Osumi, Koji; Tokuyama, Jo; Urakami, Hidejirou; Seki, Shikou; Shimada, Akira; Matsui, Akira; Isobe, Yoh; Murata, Yuya; Endo, Takashi; Ishii, Yoshiyuki; Hasegawa, Hirotoshi; Matsumoto, Sumio; Kitagawa, Yuko

doi:10.1007/s00595-011-0044-1

Cited by 22 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies (1,(4)(5)(6)8,9) reported a positive Ap53Ab expression rate of 24.0-33.1% in CRC patients. Our data were consistent with those reports in terms of the positive Ap53Ab rate.…”

Section: Discussionmentioning

confidence: 90%

“…A recent report (4) demonstrated that positive Ap53Ab expression was detected in 72 (15.1%) of 478 CRC patients with stage 0 and I disease. Another study (5) reported that 9 of 38 CRC patients (23.7%) with stage I disease exhibited positive Ap53Ab expression. In our series, the positive rate of Ap53Ab expression in stage 0 and I and only stage I cases was 16.7 and 20.0%, respectively, while that of CEA in stage 0 and I and only stage I cases was 12.5 and 13.1%, respectively.…”

Section: Discussionmentioning

confidence: 95%

“…Our data were consistent with those reports in terms of the positive Ap53Ab rate. Previous reports (4,5) suggested that the measurement of Ap53Ab was useful for the screening of CRC patients with early-stage (stage 0 and I) disease, since the positive rate of Ap53Ab expression was higher compared with that of CEA and CA19-9. There was an advantage of Ap53Ab for the detection of CRC patients with stage I disease, while the positive rate was low in CRC patients with stage 0 disease.…”

Section: Discussionmentioning

confidence: 99%

“…Previous reports (1,(4)(5)(6)8,9) have demonstrated that positive Ap53Ab expression was detected in 24.0-33.1% of CRC patients. These reports suggested that the measurement of Ap53Ab was useful for the screening of CRC patients with early-stage (stage 0 and I) disease, as the positive rate of Ap53Ab expression was higher compared with that of CEA and CA19-9.…”

Section: Introductionmentioning

confidence: 84%

“…Therefore, the development of novel molecular markers is required, using blood testing as a non-invasive method. The serum anti-p53 antibody (Ap53Ab) has been applied as a novel tumor marker for the detection of several cancers, including esophageal cancer (1,2), breast cancer (1,3) and CRC (1,4,5), from 2007 onwards in Japan. Mutations of the TP53 gene, which were detected in half of CRC cases (6), were strongly associated with carcinogenesis.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer

Kumamoto

Ishida

Kuwabara

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the usefulness of serum anti-p53 antibody (Ap53Ab) measurement for the diagnosis of colorectal cancer (CRC), and the clinical significance of the association between Ap53Ab expression and survival rate. Ap53Ab, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9 were measured by ELISA in 674 CRC patients and 115 healthy volunteers (control group). The half-life time of Ap53Ab and CEA was calculated. The association between positive Ap53Ab expression and clinicopathological characteristics, including survival rate, was analyzed. Of the 674 CRC patients, 195 (28.9%) were positive for Ap53Ab expression, while the positive rates of CEA and CA19-9 level were 39.9 and 16.9%, respectively. Positivity for Ap53Ab alone was observed in 94 patients (13.9%), whereas the positivity rate of any markers examined was 58.7%. The mean half-life of Ap53Ab and CEA was 30.7 and 11.3 days, respectively. Positive expression of Ap53Ab was significantly associated with the depth of tumor invasion (P<0.001), lymph node metastasis (P=0.024), stage (P<0.001) and CEA level (P= 0.005). No significant correlation between Ap53Ab expression and poor survival rate was observed. The positive rate of Ap53Ab was higher compared with that of CEA and CA19-9 in early-stage CRC. The combination of these markers improved the diagnostic yield of CRC up to ~60%. Furthermore, Ap53Ab expression was associated with lymph node metastasis, but not with shorter survival. These results indicated that the measurement of Ap53Ab may contribute to increased rate of detection of CRC, particularly in patients with early-stage disease, in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 84%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer

Kumamoto

Ishida

Kuwabara

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

Colorectal Cancer Circulating Biomarkers

Barderas

Villar-Vázquez

Casal

2015

Biomarkers in Cancer

View full text Add to dashboard Cite

Colorectal Cancer Circulating Biomarkers

Barderas¹,

Villar-Vázquez²,

Casal³

2014

Biomarkers in Cancer

View full text Add to dashboard Cite

Circulating CRC markers might become useful tools for the massive screening of people since they satisfy a high degree of accuracy, noninvasiveness, reproducibility, and economy. Within circulating biomarkers, we will focus on the detection of autoantibodies in serum from cancer patients and their target tumorassociated antigens (TAAs). Although the sensitivity, specificity, and predictive value of individual TAAs present low scores, the combination of multiple TAAs shows improved values to discriminate between CRC patients and controls. In this review, we outline the methodologies used to identify circulating autoantibodies and their target proteins and discuss the relevance of CRC autoantibodies for diagnosis at, particularly, early stages. An overview of the reported biomarkers is given, showing the large complexity of the autoantibody response in cancer. Different strategies to improve CRC diagnostic tests by combining autoantibodies from different studies will be discussed. Association of autoantibodies to prognosis, recurrence, and the survival of patients will be introduced. We conclude that there is a great potential for the use of autoantibodies as diagnostic CRC biomarkers in the near future. List of Abbreviations Key Facts of Circulating Biomarkers• Tumor-associated antigens (TAAs) are self-proteins altered during tumor formation and progression.• Cancer humoral responses take place against TAAs.• Autoantibodies against TAAs can be used in colorectal cancer patients as circulating biomarkers. • Immunoproteomics provide useful approaches for identifying autoantibodies and their reactive TAA targets.• Circulating autoantibodies provide an effective, reliable, and reproducible tool in cancer patients for diagnosis, prognosis, recurrence, and therapy monitoring.• Targets of circulating autoantibodies might be novel therapeutic targets for intervention. Definitions of Words and TermsBiomarker A biological marker usually a protein or glycoprotein that can be used as an indicator of a biological or pathological state or condition.TAA Tumor-associated antigen which consists of an altered self-protein able to induce an immune response in cancer patients.Autoantibody Immunoglobulin G produced in response to self-proteins altered during tumor formation or progression which can be used as a cancer biomarker.ELISA Enzyme-linked immunosorbent assay which permits to detect the presence of an immune response to a specific TAA in a biological fluid (i.e., serum or plasma) by means of an enzyme immunoassay.SEREX Acronym of serological analysis of recombinant cDNA expression libraries (SEREX) which is a technology based on the detection of tumor-associated antigens within recombinantly expressed tumor cDNA phage libraries by autologous antibodies.SERPA Acronym of serological proteome analysis where proteins from tumoral samples are resolved by 2D gels to identify TAAs by immunostaining with sera from cancer patients and controls. TAAs are then identified in a subsequent step by LC-MS.LC-MS Liquid chromatography ...

show abstract

Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients

Cited by 22 publications

References 20 publications

Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer

Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer

Colorectal Cancer Circulating Biomarkers

Colorectal Cancer Circulating Biomarkers

Contact Info

Product

Resources

About